Mark Girardi
Direktor/Vorstandsmitglied bei New England Healthcare Institute
Profil
Mark Girardi is currently a Director at New England Healthcare Institute.
Previously, he worked as a Director of Marketing Diagnostics at Cytyc Corp., a Principal at Millipore Corp., and a Vice President of Sales & Marketing at both Genzyme Genetics, Inc. and Predictive Biosciences, Inc. Girardi received his undergraduate degree from Merrimack College and his graduate degree from the University of New Hampshire.
Aktive Positionen von Mark Girardi
| Unternehmen | Position | Beginn |
|---|---|---|
New England Healthcare Institute
 New England Healthcare Institute Miscellaneous Commercial ServicesCommercial Services New England Healthcare Institute operates as a national nonprofit, nonpartisan organization composed of stakeholders from across all key sectors of health and health care. The company was founded by Henri A. Termeer in 2002 and is headquartered in Boston, MA. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Mark Girardi
| Unternehmen | Position | Ende |
|---|---|---|
| Millipore Corp. /Biosearch Division/ | Corporate Officer/Principal | - |
Cytyc Corp.
 Cytyc Corp. Medical SpecialtiesHealth Technology Cytyc Corp. manufactures and markets medical diagnostic applications. The company is headquartered in Marlborough, MA. | Vertrieb & Marketing | - |
Genzyme Genetics, Inc.
 Genzyme Genetics, Inc. Medical/Nursing ServicesHealth Services Genzyme Genetics, Inc. provides laboratory testing and diagnostic services specifically for reproductive and oncology tests. It provides tests for cystic fibrosis carriers and cancers. The company is headquartered in Westborough, MA. | Vertrieb & Marketing | - |
Predictive Biosciences, Inc.
 Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | Vertrieb & Marketing | - |
Ausbildung von Mark Girardi
| Merrimack College | Undergraduate Degree |
| University of New Hampshire | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Cytyc Corp.
Cytyc Corp. Medical SpecialtiesHealth Technology Cytyc Corp. manufactures and markets medical diagnostic applications. The company is headquartered in Marlborough, MA. | Health Technology |
| Millipore Corp. /Biosearch Division/ | Health Technology |
Genzyme Genetics, Inc.
Genzyme Genetics, Inc. Medical/Nursing ServicesHealth Services Genzyme Genetics, Inc. provides laboratory testing and diagnostic services specifically for reproductive and oncology tests. It provides tests for cystic fibrosis carriers and cancers. The company is headquartered in Westborough, MA. | Health Services |
New England Healthcare Institute
New England Healthcare Institute Miscellaneous Commercial ServicesCommercial Services New England Healthcare Institute operates as a national nonprofit, nonpartisan organization composed of stakeholders from across all key sectors of health and health care. The company was founded by Henri A. Termeer in 2002 and is headquartered in Boston, MA. | Commercial Services |
Predictive Biosciences, Inc.
Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | Health Services |
